Abstract
Background: Thrombosis prevention strategy in non-valvular atrial fibrillation, according to stroke stratification by CHA2DS2-VASc score and adding oral anticoagulation drug to treatment. Objectives: To evaluate of risk factors by cha2ds2-vasc score in Patients are diagnosed stroke with non-valvular atrial fibrillation. Method: Descriptive cross-sectional study on 91 patients are diagnosed stroke with non-valvular atrial fibrillation. Results: Average CHA2DS2-VASc score 4.80 ± 1.56 points, group ≤ 2 points accounts for 9.9%, group > 2 points accounts for 90.1%; - Risk of stroke with CHA2DS2-VASc score 4-5 points accounts for 50.5%; high risk CHA2DS2-VASc score ≥ 6 accounts for 30.8% and low risk CHA2DS2-VASc score accounts for 18.7%; - Average CHA2DS2-VASc score in female is higher than male (p < 0.01); - Average CHA2DS2-VASc score in group ≥ 75 years old is higher than in group < 75 years old; - Average CHA2DS2-VASc score in group with hypertension, heart failure, vascular diseases is higher than in group without hypertension (p< 0.05); - Average CHA2DS2-VASc score in group with diabetes is higher than in group without diabetes (p>0.05); - Average CHA2DS2-VASc score in group with pre-stroke is higher than in group without pre-stroke (p<0.01). Conclusion: CHA2DS2-VASc score is easily applicable and is recommended in routinely clinical practice.